{"id":"NCT03602053","sponsor":"Centre for Infectious Disease Research in Zambia","briefTitle":"Study of BBIL's ROTAVAC® and ROTAVAC 5CM Vaccines in Zambia","officialTitle":"An Open-label, Randomized, Controlled, Single Centre, Phase IIb Study to Assess the Immunogenicity, Reactogenicity and Safety of Three Live Oral Rotavirus Vaccines, ROTAVAC® , ROTAVAC 5CM and Rotarix® in Healthy Zambian Infants","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2019-01-22","primaryCompletion":"2019-10-04","completion":"2019-10-04","firstPosted":"2018-07-26","resultsPosted":"2020-12-19","lastUpdate":"2020-12-19"},"enrollment":450,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Diarrhea","Diarrhea Rotavirus"],"interventions":[{"type":"BIOLOGICAL","name":"ROTAVAC®","otherNames":[]},{"type":"BIOLOGICAL","name":"ROTAVAC 5D","otherNames":[]},{"type":"BIOLOGICAL","name":"Rotarix®","otherNames":[]}],"arms":[{"label":"ROTAVAC 5D","type":"EXPERIMENTAL"},{"label":"ROTAVAC®","type":"EXPERIMENTAL"},{"label":"Rotarix®","type":"ACTIVE_COMPARATOR"}],"summary":"The study is being conducted to evaluate and compare the immunogenicity of ROTAVAC® and ROTAVAC 5D 28 days after the last dose of the vaccine, when administered to infants in a three-dose schedule at 6, 10 and 14 weeks of age.\n\nThe study will also assess the reactogenicity of the vaccine 7 days after each vaccination and safety from first vaccination up to 4 weeks after the last vaccination with ROTAVAC® and ROTAVAC 5D, and of Rotarix® when administered to infants in a two-dose schedule at 6 and 10 weeks of age.","primaryOutcome":{"measure":"Geometric Mean Concentration Using WC3 as the Viral Lysate","timeFrame":"28 day after last dose of the study vaccine","effectByArm":[{"arm":"ROTAVAC 5D®","deltaMin":18.1,"sd":null},{"arm":"ROTAVAC®","deltaMin":14,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"6 Weeks","sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["Zambia"]},"refs":{"pmids":["27059362","22520139","27059353","22579125","26974432","27558938","20107214","20692030","20692031","24629994","28328346","27059354","19799704","15484186","19817593","20472032","17919334","19056806","19939844","16394298","25091663","8133107","8393054","2172405","24374502","6304516","16088802","1650128","14551493","20220306","39115","2999315","7966566","3028333","17109346","28242070","16735085","19545211","28560356","29543547"],"seeAlso":["https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Rotarix/pdf/ROTARIX-PI-PIL.PDF","https://www.merck.com/product/usa/pi_circulars/r/rotateq/rotateq_ppi.pdf","https://www.path.org/media-center/path-welcomes-new-promising-study-results-for-rotavirus-vaccine-candidate/","http://www.pharmabiz.com/NewsDetails.aspx?aid=108851&sid=2"]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":137},"commonTop":["Upper Respiratory Tract Infection","Respiratory Tract Infection","Diarrhoea","Rhinitis","Conjuntivities"]}}